Loomis, Sayles & Company
ADPT icon

Loomis, Sayles & Company’s Adaptive Biotechnologies ADPT Stock Holding History

Loomis, Sayles & Company’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-244
Closed -$10K – 825
2021
Q1 		$10K Buy
244
+15
+7% +$812 ﹤0.01% 774
2020
Q4 		$14K Buy
+229
New +$11.8K ﹤0.01% 661
2019
Q4 		– Sell
-448,637
Closed -$13.9M – 730
2019
Q3 		$13.9M Buy
448,637
+112,595
+34% +$4.6M 0.03% 280
2019
Q2 		$16.2M Buy
+336,042
New +$14.9M 0.03% 240

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company's ADPT Position: Q2 2021 in Review

Loomis, Sayles & Company sold out of Adaptive Biotechnologies (ADPT) in Q2 2021, closing a stake of 244 shares — an estimated $10K sold.

Loomis, Sayles & Company first reported a position in ADPT in Q2 2019 and held it in 4 quarters. The position peaked at $16.2M in Q2 2019. 230 funds tracked by Wall St. Rank hold ADPT as of Q2 2021.

  • Loomis, Sayles & Company reported no remaining Adaptive Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 244 Adaptive Biotechnologies shares in Q2 2021, an estimated $10K.
  • Loomis, Sayles & Company first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 4 quarters.
  • Loomis, Sayles & Company's Adaptive Biotechnologies position peaked at $16.2M in Q2 2019.
  • 230 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2021.

Based on Loomis, Sayles & Company's 13F filing for Q2 2021, filed 13 Aug 2021.